No abstract

No abstract

Background: In order to reduce Centers for Medicare and Medicaid Services (CMS)directed readmission penalties and improve patient discharge care, a bedside discharge medication delivery service was developed.Objective: To evaluate the impact of a bedside discharge medication delivery and pharmacist consultation service (Meds-to-Beds; MtB) on 30-day readmission rates at an academic hospital. Methods: The pharmacist-led MtB program was established in September 2016. Unplanned 30-day readmission data and other disease severity indicators were retrospectively collected from September 2015 to January 2017. Readmission data were compared for patients discharged prior to availability of the MtB program vs patients who participated in the program. Results: A total of 174 MtB patients and 170 control patients were included. There were significantly fewer 30-day readmissions in the MtB group (n = 14, 8.0%) compared with the control group (n = 28, 16.5%, P = 0.02). MtB participation was found to decrease the odds of a 30-day readmission (odds ratio = 0.40, 95% confidence interval 0.190, 0.843, P = 0.016). Conclusions: A care transition program in the form of a bedside medication delivery and pharmacist consultation service was associated with a lower likelihood of 30-day hospital readmission. K E Y W O R D S community pharmacy services, medication reconciliation, medication therapy management, patient transfer, pharmacy service, hospital, patient readmission

Stenotrophomonas maltophilia is an inherently multidrug resistant (MDR) opportunistic pathogen with many mechanisms of resistance. SENTRY studies reveal decreasing sensitivities of S. maltophilia to trimethoprim-sulfamethoxazole and fluoroquinolones. Ceftolozane-tazobactam (Zerbaxa, Merck & Co., Inc.) a novel intravenous combination agent of a third-generation cephalosporin and β-lactamase inhibitor was demonstrated to have in vitro activity against many Gram-positive, Gram-negative, and MDR organisms. Data for ceftolozane-tazobactam's use outside of Food and Drug Administration (FDA) approved indications has been limited thus far to two case reports which demonstrated its efficacy in pan-resistant Pseudomonas aeruginosa pneumonia. Herein, we describe the first published case of treatment of MDR S. maltophilia in polymicrobial osteomyelitis with long-term (>14 days) ceftolozane-tazobactam and metronidazole. Ceftolozane-tazobactam may offer a possible alternative for clinicians faced with limited options in the treatment of resistant pathogens including MDR S. maltophilia.